Search
for
Sort by
Research 421–450 of 1000+
- Dermal Fibrosis and the Current Scope of Hydrogel Strategies for Scarless Wound Healing
- Differences in male and female pattern hair loss based on androgens, estrogen, iron, vitamin D, lipid metabolism, and genetic regulation
- Management of Alopecia Areata through Unani Medicine
- Squamous Cell Carcinoma of the Scalp Following Synthetic Hair Implantation: A Structured Narrative Review and the Seventh Case Reported in Literature
- Delphi Consensus on Attenuated Androgen Use for Long‐Term Prophylaxis in Hereditary Angioedema: AURA Project
- Exploring lncRNA-Mediated Mechanisms in Muscle Regulation and Their Implications for Duchenne Muscular Dystrophy
- The Relationship Between Nutrition Habits, BMI, Anxiety, and Seborrheic Dermatitis
- Ovarian Hyperthecosis Presenting as Polycythemia
- Effects of Nannochloropsis salina Fermented Oil on Proliferation of Human Dermal Papilla Cells and Hair Growth
- Quality-of-Life Assessment in Singaporean Children with Alopecia Areata
- The Need and Management of hormone Imbalances in Women
- Corona With Lyme: A Long COVID Case Study
- Pimples and pustules in diabetes
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Neurological post‐acute sequelae of SARS‐CoV‐2 infection
- Bupropion for the treatment of fluoxetine non-responsive trichotillomania: a case report
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- A 32‐year‐old woman with arthralgias and severe hypotension
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Alopecia Areata of the Nails: Diagnosis and Management
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- Exploring novel management options for alopecia areata
- Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
- A Well‐Tolerated Hair Serum Containing New Natural Active Ingredients Reduced Hair Loss and Improved Quality of Life in Women With Chronic Telogen Effluvium: A 16‐Week Controlled Study
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis
- COPD at the end of life: Predictors of the emotional distress of patients and their family caregivers